References
- Kreitman R J, Margulies I, Stetler-Stevenson M, Wang Q -C, FitzGerald D PJ, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 2000; 6: 1476–1487
- Ho M, Kreitman R J, Onda M, Pastan I. In vitro antibody evoluation targeting germline hotspots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 2005; 280: 607–617
- Queen C, Schneider W P, Selick H E, Payne P W, Landolfi N P, Duncan J F, et al. A humanized antibody that binds to the interleukin-2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029–10033
- Pastan I, Hassan R, FitzGerald D J, Kreitman R J. Iummnotoxin treatment of cancer. Ann Rev Med 2007; 58: 37.1–37.16
- Kreitman R J, Pastan I. Immunotoxins for the treatment of hematological malignancies. Curr Drug Target 2006; 7: 1301–1311
- Braschoss S, Hirsch B, Dübel S, Stein H, Dürkop H. New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo. Leuk Lymphoma 2007; 48: 1179–1186
- Chang C -H, Sapra P, Vanama S S, Hansen H J, Horak I D, Goldenberg D M. Effective therapy of human lymphoma xenographs with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005; 106: 4308–4314
- Huhn M, Sasse S, Tur M K, Matthey B, Schinkothe, Rybak S M, et al. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 2001; 61: 8737–8742
- Koon H B, Junghans R P. Anti-CD30 antibody-based therapy. Curr Opin Oncol 2000; 12: 588–593
- Barth S, Huhn M, Matthey B, Tawadros S, Schnell R, Schinkothe T, Diehl V, et al. K-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin's tumors in SCID mice. Blood 2000; 95: 3909–3914
- Falini B, Bolognesi A, Flenghi L, Tazzari P L, Broe M K, Stein H, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195–1196
- Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, et al. A phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8: 1779–1786